Femme-Tab ED 20/100 is the first low oestrogen contraceptive pill added to PBS schedule in Australia

The Pharmaceutical Benefits Scheme (Australia) has added a low oestrogen dose combined oral contraceptive (COC) pill for the first time to its schedule of subsidised medicines from 1 July 2013.

This product is Femme-Tab ED 20/100, which AFT Pharmaceuticals has introduced to the Australian market, complete with PBS subsidisation.

Femme-Tab ED 20/100 tablets contain levonorgestrel 100 micrograms and ethinyloestradiol 20 micrograms.

Full details of Femme-Tab ED 20/100, including indications and usage, contraindications, adverse reactions and interactions with other medications can be found at www.aftpharm.com.

 

Similar articles

AFT and RooLife launch OTC medicines online in China

AFT and RooLife launch OTC medicines online in China

AFT Pharmaceuticals and RooLife Group today announce they have launched a range of AFT’s over the counter (OTC) pharmaceuticals through their store on the China Cross Border E-Commerce (CBEC) online platform Tmall Global.

Read more

Announcement for FY19 Full Year Results

*AFT Pharmaceuticals to announce full year results on Wednesday May 22 2019*

Read more

New Maxigesic Agreement For Aft Pharmaceuticals With Leading Nordic Consumer Health Company

New Maxigesic agreement for AFT Pharmaceuticals with Leading Nordic Consumer Health Company in Sweden, Norway, Finland, Denmark and Iceland

AFT Pharmaceuticals (‘AFT’) has licensed the product line of its patented combination painkiller, Maxigesic, in the Nordic region to Weifa AS (‘Weifa’).

Read more